Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$220.83-1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · BIIB
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $221 BIIB trades at 16× p/e, below its 22× p/e peer median. Our $303 fair value sits well above the price. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $157–$300. Note: our $303 fair value sits above the entire analyst range ($157–$300). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $240.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $648.54 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $781.04 | — | — | Hist. CAGR | high |
| graham number | 12M | $199.60 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$157.00 – $300.00 (median $240.00) · 20 analysts · as of 2026-09-03
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 20% over what the business is worth with no growth; closing that gap needs roughly 13.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $13.09/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $259.30 |
| 15.9 |
| 19.18 |
| TTM |
| high |
| Peer P/FCF | 12M | $391.44 | 21.6 | 18.13 | TTM | high |
| Peer P/E | 12M | $276.03 | 18.1 | 15.24 | ntm analyst | high |
| Peer P/S | 12M | $767.56 | 11.4 | 67.44 | TTM | high |
| PEG | 12M | $176.26 | 12.6 | 13.97 | TTM | high |
| residual income | 12M | $133.82 | — | — | TTM | high |
| Own P/E history | 12M | $178.75 | 12.8 | 13.97 | TTM | high |
| triangulated | 12M | $336.50 | 22.0 | 15.30 | Triangulated | high |
| Peer P/FCF | 3Y | $595.33 | 21.6 | 27.58 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $419.70 | 18.1 | 23.17 | Analyst | medium |
| Peer P/S | 3Y | $813.72 | 11.4 | 71.49 | guidance | medium |
| PEG | 3Y | $292.32 | 12.6 | 23.17 | Analyst | medium |
| Own P/E history | 3Y | $296.45 | 12.8 | 23.17 | Analyst | medium |
| Peer P/FCF | 5Y | $787.32 | 21.6 | 36.48 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $418.00 | 18.1 | 23.07 | Analyst | high |
| Peer P/S | 5Y | $810.41 | 11.4 | 71.20 | guidance | high |
| PEG | 5Y | $291.13 | 12.6 | 23.07 | Analyst | high |
| Own P/E history | 5Y | $295.24 | 12.8 | 23.07 | Analyst | high |